Cargando…

Novel Experimental Drugs for Treatment of Multiple Myeloma

Multiple myeloma (MM) is the second most frequent hematological malignancy characterized by bone marrow aberrant plasma cells proliferation leading to a genetic complex and heterogeneous disease, with a median survival ranging from two to more than 10 years. By using new drugs such as proteasome inh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Offidani, Massimo, Corvatta, Laura, Morè, Sonia, Olivieri, Attilio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955760/ https://www.ncbi.nlm.nih.gov/pubmed/33727866 http://dx.doi.org/10.2147/JEP.S265288

Ejemplares similares

Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety
por: Offidani, Massimo, et al.
Publicado: (2021)

Current Main Topics in Multiple Myeloma
por: Morè, Sonia, et al.
Publicado: (2023)

Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment
por: Morè, Sonia, et al.
Publicado: (2020)

Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments
por: Offidani, Massimo, et al.
Publicado: (2021)

Novel Immunotherapies and Combinations: The Future Landscape of Multiple Myeloma Treatment
por: Morè, Sonia, et al.
Publicado: (2023)

P973: ATTRITION PROBABILITY AND PREDICTORS AMONG MULTIPLE MYELOMA PATIENTS TREATED IN AN ITALIAN HAEMATOLOGICAL TERTIARY CARE CENTRE
por: More’, Sonia, et al.
Publicado: (2023)

P912: ADDING REFRACTORINESS STATUS TO LINES OF THERAPY BETTER DEFINE PROGNOSIS OF A REAL LIFE ITALIAN MULTIPLE MYELOMA POPULATION
por: More’, Sonia, et al.
Publicado: (2023)

Autologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go?
por: Morè, Sonia, et al.
Publicado: (2022)

P47 REAL-WORLD DATA OF ATTRITION RATES BY SUBSEQUENT LINES OF THERAPY IN MULTIPLE MYELOMA PATIENTS TREATED IN A TERTIARY CARE ITALIAN CENTRE
por: Morè, S., et al.
Publicado: (2023)

An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma
por: Offidani, Massimo, et al.
Publicado: (2014)

Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences
por: Morè, Sonia, et al.
Publicado: (2023)

P25: CARFILZOMIB-BASED TREATMENTS COULD BE ADDED TO IMPEDE-VTE SCORE TO BETTER PREDICT VENOUS THROMBOEMBOLIC RISK IN MM PATIENTS
por: Morè, S, et al.
Publicado: (2022)

Introduction to “Immunotherapies for Multiple Myeloma”
por: Offidani, Massimo, et al.
Publicado: (2020)

PB2024: PREVALENCE OF TYPE 1 GAUCHER DISEASE IN PATIENTS WITH MULTIPLE MYELOMA: FIRST INTERIM ANALYSIS OF A PROSPECTIVE, MULTICENTER, OBSERVATIONAL STUDY
por: Offidani, M., et al.
Publicado: (2022)

Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study
por: Offidani, M, et al.
Publicado: (2013)

Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients
por: Ria, Roberto, et al.
Publicado: (2020)

Three Drug Combinations in the Treatment of Fit Elderly Multiple Myeloma Patients
por: Gardeney, Hélène, et al.
Publicado: (2020)

Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration
por: Nabissi, Massimo, et al.
Publicado: (2016)

Melflufen: A Peptide–Drug Conjugate for the Treatment of Multiple Myeloma
por: Mateos, María-Victoria, et al.
Publicado: (2020)

Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
por: Landgren, Ola, et al.
Publicado: (2019)

Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma
por: Fostier, Karel, et al.
Publicado: (2012)

Immunotherapy: A Novel Era of Promising Treatments for Multiple Myeloma
por: Castella, Maria, et al.
Publicado: (2018)

Autophagy and Apoptosis: Current Challenges of Treatment and Drug Resistance in Multiple Myeloma
por: Al-Odat, Omar S., et al.
Publicado: (2022)

Current and Novel Alkylators in Multiple Myeloma
por: Schjesvold, Fredrik, et al.
Publicado: (2021)

Development of Novel Immunotherapies for Multiple Myeloma
por: Al-Hujaily, Ensaf M., et al.
Publicado: (2016)

Elotuzumab for the treatment of multiple myeloma
por: Wang, Yucai, et al.
Publicado: (2016)

Pathogenesis and treatment of multiple myeloma
por: Yang, Peipei, et al.
Publicado: (2022)

Molecular mechanisms in multiple myeloma drug resistance
por: Nikesitch, Nicholas, et al.
Publicado: (2016)

Emerging drugs and combinations to treat multiple myeloma
por: Larocca, Alessandra, et al.
Publicado: (2017)

Anti-Angiogenic Activity of Drugs in Multiple Myeloma
por: Saltarella, Ilaria, et al.
Publicado: (2023)

Place in therapy of innovative drugs in multiple myeloma in 2021 and 2023 according to an expert panel Delphi consensus
por: Mario, Boccadoro, et al.
Publicado: (2021)

Salvage Therapy of Multiple Myeloma: The New Generation Drugs
por: Romano, Alessandra, et al.
Publicado: (2014)

Front line treatment of elderly multiple myeloma in the era of novel agents
por: Venon, Marie-Dominique, et al.
Publicado: (2009)

Novel agents in the treatment of multiple myeloma: a review about the future
por: Naymagon, Leonard, et al.
Publicado: (2016)

Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma
por: Tai, Waqqas, et al.
Publicado: (2022)

Experts’ consensus on the definition and management of high risk multiple myeloma
por: Marcon, Chiara, et al.
Publicado: (2023)

Pomalidomide for the Treatment of Multiple Myeloma
por: Clark, Stephen M., et al.
Publicado: (2014)

Anti-BCMA novel therapies for multiple myeloma
por: Sammartano, Vincenzo, et al.
Publicado: (2023)

Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma
por: Radocha, Jakub, et al.
Publicado: (2021)

New drugs in multiple myeloma – role of carfilzomib and pomalidomide
por: Jurczyszyn, Artur, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_8gvlsooa2li7pb35ummni8cbcn